Trade and tariff analytics
2026-04-26
11 minute read
20 sources
Trump pharma tariffs and the US drug supply chain through 2026: Section 232, Ireland exposure, and the API reshoring arithmetic
The April 2025 Section 232 pharmaceuticals investigation, the Ireland headline import number, and the India and China API base together define the 2026 corridor. We map the import stack, the announced reshoring capex, the IRA Year 2 negotiation list, and the 2026 to 2028 buyer playbook.
The Trump administration commenced a Section 232 pharmaceuticals investigation on April 1, 2025 under the Bureau of Industry and Security (BIS) at the Department of Commerce, with public threats of duties between 25 and 200 percent on imported finished drugs and active pharmaceutical ingredients (APIs). United States imports under Harmoni...